Amgen resumed with a Neutral at BofA

BofA resumed coverage of Amgen with a Neutral rating and $290 price target after the Horizon Therapeutics deal closed following “almost a year of tortuous FTC review.” Overall, the firm thought the Horizon deal “made good strategic sense,” but growth concerns and emerging loss of exclusivity concerns keep BofA at a Neutral rating.